

Jennifer A Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2297610/publications.pdf>

Version: 2024-02-01

39
papers

4,075
citations

218677

26
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

6441
citing authors

#	ARTICLE	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
2	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. <i>Nature Genetics</i> , 2014, 46, 451-456.	21.4	525
3	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. <i>Nature</i> , 2019, 572, 67-73.	27.8	293
4	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology, The</i> , 2016, 17, 484-495.	10.7	274
5	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology, The</i> , 2018, 19, 785-798.	10.7	268
6	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	16.8	191
7	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. <i>Nature Genetics</i> , 2014, 46, 39-44.	21.4	167
8	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. <i>Lancet Oncology, The</i> , 2015, 16, 569-582.	10.7	147
9	An in vivo patient-derived model of endogenous IDH1-mutant glioma. <i>Neuro-Oncology</i> , 2012, 14, 184-191.	1.2	145
10	RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. <i>Cancer Research</i> , 2015, 75, 3623-3635.	0.9	133
11	Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. <i>Nature Communications</i> , 2020, 11, 4997.	12.8	109
12	The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280.	27.8	94
13	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
14	Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes. <i>Stem Cell Reports</i> , 2015, 5, 1-9.	4.8	72
15	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	16.8	69
16	Proneural bHLH Genes in Development and Disease. <i>Current Topics in Developmental Biology</i> , 2014, 110, 75-127.	2.2	65
17	Heparan Sulfate Proteoglycans Containing a Glypican 5 Core and 2-O-Sulfo-iduronic Acid Function as Sonic Hedgehog Co-receptors to Promote Proliferation. <i>Journal of Biological Chemistry</i> , 2013, 288, 26275-26288.	3.4	64
18	Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. <i>Cancer Cell</i> , 2022, 40, 379-392.e9.	16.8	54

#	ARTICLE	IF	CITATIONS
19	The CHD6 chromatin remodeler is an oxidative DNA damage response factor. <i>Nature Communications</i> , 2019, 10, 241.	12.8	45
20	Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 19098-19108.	7.1	42
21	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. <i>Neuro-Oncology</i> , 2017, 19, 1607-1617.	1.2	39
22	A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors. <i>Nature Medicine</i> , 2017, 23, 1191-1202.	30.7	38
23	Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. <i>Oncotarget</i> , 2014, 5, 7960-7979.	1.8	35
24	Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors. <i>Nature Communications</i> , 2019, 10, 2000.	12.8	34
25	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	7.7	34
26	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells. <i>American Journal of Pathology</i> , 2016, 186, 446-459.	3.8	32
27	Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. <i>Acta Neuropathologica</i> , 2021, 141, 725-754.	7.7	32
28	CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. <i>Cancer Research</i> , 2018, 78, 4745-4759.	0.9	31
29	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. <i>Cancer Research</i> , 2019, 79, 2111-2123.	0.9	28
30	An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. <i>Nature Communications</i> , 2020, 11, 3627.	12.8	21
31	Copy-scAT: Deconvoluting single-cell chromatin accessibility of genetic subclones in cancer. <i>Science Advances</i> , 2021, 7, eabg6045.	10.3	19
32	A high-throughput alpha particle irradiation system for monitoring DNA damage repair, genome instability and screening in human cell and yeast model systems. <i>Nucleic Acids Research</i> , 2020, 48, e111-e111.	14.5	13
33	Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. <i>Clinical Cancer Research</i> , 2021, 27, 1807-1820.	7.0	12
34	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. <i>Cancer Medicine</i> , 2020, 9, 447-459.	2.8	11
35	Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. <i>Communications Biology</i> , 2022, 5, .	4.4	8
36	Unilateral Foot Drop as an Initial Presentation of a Brain Tumor in a Child. <i>Journal of Child Neurology</i> , 2014, 29, 955-958.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Population Based Analysis Ependymoma Patients in Alberta from 1975 to 2007. Canadian Journal of Neurological Sciences, 2014, 41, 742-747.	0.5	3
38	TMIC-02CELL AUTONOMOUS AND CELL NON-AUTONOMOUS ROLES OF p75 NEUROTROPHIN RECEPTOR (p75NTR) IN GLIOMA INVASION. Neuro-Oncology, 2015, 17, v214.6-v214.	1.2	0
39	RARE-19. Molecular characterization and treatment response of metastatic DIA/DIG. Neuro-Oncology, 2022, 24, i13-i14.	1.2	0